"A pilot survey into the landscape of neuro-oncology care in the commun" by Christine Lu-Emerson, Sajeel Chowdhary et al.
 

A pilot survey into the landscape of neuro-oncology care in the community

Christine Lu-Emerson, Department of Neurology, Maine Medical Partners and Maine Health Cancer Care, South Portland, ME 04106, United States.
Sajeel Chowdhary, Department of Neuro-Oncology, Tampa General Hospital Cancer Institute, University of South Florida, Tampa, Florida 33606, United States.
Rupesh Kotecha, Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, United States.
Akanksha Sharma, Pacific Neuroscience Institute and Providence Saint John's Cancer Institute, Santa Monica, CA 90404, United States.
Yazmin Odia, Department of Neuro-oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, United States.
Brian Vaillant, Department of Neurology, University of Texas at Austin, Austin, TX 78712, United States.
Charles Redfern, Laurel Amtower Cancer Institute, 3075 Health Center Dr, San Diego, CA 92123, United States.
Aaron Mammoser, Department of Neuroscience and Oncology, Piedmont Brain Tumor Center, Piedmont Atlanta Hospital, Atlanta, GA 30309, United States.
Kent Shih, Tennessee Oncology, Plaza II, Nashville, TN 37203, United States.
Santosh Kesari, Pacific Neuroscience Institute and Providence Saint John's Cancer Institute, Santa Monica, CA 90404, United States.
Richard Peterson, Regions Hospital, St. Paul, MN 55101, United States.
Bret Friday, Essentia Health, Duluth, MN 55805, United States.
W Jeffery Edenfield, Prisma Health Cancer Institute, 65 International Dr, Greenville, SC 29615, United States.
Sebastian Koga, Koga Neurosurgery, STE C, Covington, LA 70433, United States.
James Snyder, Department of Neurosurgery and Neurology, Hermelin Brain Tumor Center, Henry Ford Health, Detroit, MI 48202, United States.
Jerry Jaboin, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States.
Isaac Melguizo-Gavilanes, Advocate Health - MidwestFollow
Melissa McCabe, Good Samaritan University Hospital, West Islip, NY 11795, United States.
Michael Humeniuk, Gibbs Cancer Center, Spartanburg Regional Healthcare System, Spartanburg, SC 29303, United States.
Prakash Ambady, Providence Brain & Spine Institute, Portland, OR 97225, United States.
Erin Dunbar, Department of Neuroscience and Oncology, Piedmont Brain Tumor Center, Piedmont Atlanta Hospital, Atlanta, GA 30309, United States.

Affiliations

Aurora Cancer Care, Milwaukee

Abstract

Background:The complexities of the field of neuro-oncology require multidisciplinary collaboration in order to deliver contemporary comprehensive care. There is increasing awareness that much of neuro-oncology care occurs in the community setting. In 2022, the Society for Neuro-Oncology (SNO) created the Community Neuro-Oncology Committee (CNO) in an inaugural attempt to formally acknowledge community neuro-oncology practitioners.

Methods:A 19 question survey was developed by SNO-CNO to gather initial data on the current landscape of neuro-oncology care in the community. The survey was distributed via the SNO newsletter and email blasts as well as through partnerships with multiple advocacy groups. Results were analyzed and tabulated through R2.

Results:There were 112 responses from providers in the United States and Canada. Most providers were physicians and represented multiple disciplines including neurology, neuro-oncology, medical oncology, neurosurgery, and radiation oncology. Sixty-four (57%) described themselves as neuro-oncology-focused. Eighty-eight (79%) reported access to neuro-oncology tumor boards. Sixty-eight (73%) stated they had access to molecular tumor boards. Most respondents felt that they were adequately supported to manage neuro-oncology patients. When dividing responses based on a neuro-oncology-focused practice compared to a less neuro-oncology-focused practice, there were significant differences between access to molecular tumors boards (85% vs 63%, P = .023) and access to clinical trials (98% vs 82%, P = .022).

Conclusion:This qualitative and quantitative hypothesis-generating data is the start of understanding the challenges faced by community neuro-oncology providers. These results will guide future studies and recommendations aimed toward better supporting them and their patients.

Document Type

Article

PubMed ID

40163684

Teammate Access


 

Share

COinS